Aspirin Therapy for Coronary Artery Disease
For adults with documented coronary artery disease, aspirin 75-100 mg daily is recommended lifelong as the standard antiplatelet therapy regimen. 1
Clinical Algorithm for Aspirin Dosing in CAD
Standard Regimen (Most Patients)
- Dose: 75-100 mg daily, taken lifelong 1
- This applies to:
The 2024 ESC Guidelines provide the strongest evidence (Class I, Level A recommendation) for this dosing strategy, representing an upgrade from previous recommendations that were more tentative about aspirin use in patients without prior MI or revascularization 1.
Post-PCI Specific Considerations
Immediately after PCI with stenting:
- Dual antiplatelet therapy (DAPT): Aspirin 75-100 mg + clopidogrel 75 mg daily for up to 6 months as the default strategy 1
- After completing DAPT duration, continue aspirin 75-100 mg daily lifelong 1
High bleeding risk patients:
- Discontinue DAPT at 1-3 months post-PCI
- Continue single antiplatelet therapy (aspirin or clopidogrel) 1
Alternative to Aspirin
If aspirin intolerance or contraindication exists:
- Clopidogrel 75 mg daily is recommended as a safe and effective alternative (Class I, Level A) 1
- This represents an upgrade in evidence strength from previous guidelines
Patients Requiring Oral Anticoagulation
For CAD patients with atrial fibrillation or other OAC indications:
- Long-term: Direct oral anticoagulant (DOAC) alone is preferred over combination therapy 1
- Post-PCI: Triple therapy (aspirin + clopidogrel + OAC) for ≤1 week, then dual therapy (clopidogrel + OAC) for 6-12 months depending on ischemic risk, followed by OAC alone 1
Key Evidence Strengths and Nuances
The 2024 ESC Guidelines 1 represent the most current and authoritative evidence, with several important updates:
Strengthened recommendation for imaging-documented CAD: The recommendation for aspirin in patients with obstructive CAD but no prior MI/revascularization was upgraded from Class IIb (Level C) to Class I (Level B) 1. This reflects growing evidence that aspirin benefits extend beyond just post-event secondary prevention.
Clopidogrel as true alternative: The evidence for clopidogrel as an aspirin alternative was upgraded to Class I, Level A 1, making it a fully equivalent option rather than merely acceptable.
Dose consistency: The 75-100 mg daily dose is consistently recommended across all CAD scenarios. Higher doses (e.g., 325 mg) are not recommended for chronic therapy, as they increase bleeding risk without improving efficacy 2, 3, 4.
Common Pitfalls to Avoid
Do not use higher maintenance doses: Aspirin doses >100 mg daily increase bleeding risk without additional cardiovascular benefit 3, 4. The evidence clearly favors 75-100 mg for chronic therapy.
Do not discontinue aspirin prematurely: Aspirin should be continued lifelong in CAD patients unless specific contraindications develop 1. Recent trends toward P2Y12 inhibitor monotherapy are still being evaluated and are not yet standard practice for most CAD patients 5, 6.
Do not forget gastroprotection: A proton pump inhibitor is recommended in patients at increased gastrointestinal bleeding risk during antiplatelet therapy 1.
Post-PCI timing matters: After PCI, aspirin should be initiated immediately post-operatively once bleeding concerns are addressed 1. The DAPT duration (typically 6 months) should be completed before transitioning to aspirin monotherapy.
Aspirin intolerance requires action: If true aspirin allergy or intolerance exists, switch to clopidogrel 75 mg daily—do not leave the patient without antiplatelet therapy 1.
Safety Considerations
Monitor for:
- Gastrointestinal bleeding (most common adverse effect)
- Easy bruising or bleeding
- Contraindications: Active peptic ulcer disease, severe bleeding disorders, aspirin hypersensitivity 7
The 75-100 mg dose provides optimal balance between thrombotic protection and bleeding risk across diverse CAD populations 2, 3, 5.